Brookstone Capital Management buys $4,033,764 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Brookstone Capital Management scooped up 7,885 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 63,614 shares of AbbVie Inc which is valued at $4,033,764.AbbVie Inc makes up approximately 0.52% of Brookstone Capital Management’s portfolio.

Other Hedge Funds, Including , Osborne Partners Capital Management boosted its stake in ABBV in the latest quarter, The investment management firm added 2,711 additional shares and now holds a total of 52,466 shares of AbbVie Inc which is valued at $3,326,869. AbbVie Inc makes up approx 0.48% of Osborne Partners Capital Management’s portfolio.Premier Asset Managment boosted its stake in ABBV in the latest quarter, The investment management firm added 1,980 additional shares and now holds a total of 27,175 shares of AbbVie Inc which is valued at $1,723,167. AbbVie Inc makes up approx 0.42% of Premier Asset Managment’s portfolio. Acropolis Investment Management added ABBV to its portfolio by purchasing 1,711 company shares during the most recent quarter which is valued at $108,751. AbbVie Inc makes up approx 0.02% of Acropolis Investment Management’s portfolio.Neville Rodie Shaw Inc reduced its stake in ABBV by selling 8,110 shares or 4.19% in the most recent quarter. The Hedge Fund company now holds 185,436 shares of ABBV which is valued at $12,010,690. AbbVie Inc makes up approx 1.40% of Neville Rodie Shaw Inc’s portfolio.Capstone Asset Management Co boosted its stake in ABBV in the latest quarter, The investment management firm added 59,231 additional shares and now holds a total of 205,199 shares of AbbVie Inc which is valued at $13,290,739. AbbVie Inc makes up approx 0.39% of Capstone Asset Management Co’s portfolio.

AbbVie Inc opened for trading at $63.57 and hit $63.9 on the upside on Wednesday, eventually ending the session at $63.41, with a gain of 0.14% or 0.09 points. The heightened volatility saw the trading volume jump to 75,02,821 shares. Company has a market cap of $102,557 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.